Abstract
The COVID-19 pandemic has taken a significant toll on people worldwide, and there are currently no specific antivirus drugs or vaccines. Herein it is a therapeutic based on catalase, an antioxidant enzyme that can effectively breakdown hydrogen peroxide and minimize the downstream reactive oxygen species, which are excessively produced resulting from the infection and inflammatory process, is reported. Catalase assists to regulate production of cytokines, protect oxidative injury, and repress replication of SARS-CoV-2, as demonstrated in human leukocytes and alveolar epithelial cells, and rhesus macaques, without noticeable toxicity. Such a therapeutic can be readily manufactured at low cost as a potential treatment for COVID-19.
Keywords:
SARS-Cov-2; anti-inflammation; catalase; immunosuppression.
© 2020 Wiley-VCH GmbH.
MeSH terms
-
Animals
-
Anti-Inflammatory Agents / pharmacokinetics
-
Anti-Inflammatory Agents / therapeutic use*
-
Antioxidants / pharmacokinetics
-
Antioxidants / therapeutic use*
-
Betacoronavirus / drug effects*
-
Betacoronavirus / physiology
-
COVID-19
-
Catalase / pharmacokinetics
-
Catalase / therapeutic use*
-
Cell Line
-
Coronavirus Infections / drug therapy*
-
Coronavirus Infections / metabolism
-
Coronavirus Infections / virology
-
Humans
-
Leukocytes / drug effects
-
Leukocytes / metabolism
-
Leukocytes / virology
-
Macaca mulatta
-
Mice
-
Mice, Inbred BALB C
-
Oxidative Stress / drug effects
-
Pandemics
-
Pneumonia, Viral / drug therapy*
-
Pneumonia, Viral / metabolism
-
Pneumonia, Viral / virology
-
Pulmonary Alveoli / drug effects
-
Pulmonary Alveoli / metabolism
-
Pulmonary Alveoli / virology
-
SARS-CoV-2
-
Virus Replication / drug effects
Substances
-
Anti-Inflammatory Agents
-
Antioxidants
-
Catalase